BELLEVILLE, Ontario, June 18 /PRNewswire-FirstCall/ -- Bioniche Life Sciences Inc. (TSX: BNC), a fully-integrated human and animal biopharmaceutical company, today announced that it has received approval from the Canadian Veterinary Drugs Directorate to sell its proprietary product, Enhance(R), for intra-articular injection in horses. Enhance(R) is used to treat synovitis and/or osteoarthrosis. It is the Company’s intent to register these claims in other jurisdictions as well.
“We are very pleased to receive this approval from the Veterinary Drugs Directorate,” said Rick Culbert, President of Bioniche Animal Health Canada, a Division of Bioniche Life Sciences Inc. “Enhance(R) has been a very successful product for us in Australia, and we look forward to making it available to our Canadian veterinary customers.”
Enhance(R) is a sterile sodium hyaluronate solution, obtained from a selective fermentation source using a manufacturing process that is free from thermal degrading effects. The manufacturing occurs at a Bioniche owned and operated facility in Galway, Ireland.
“It is gratifying to be able to offer one more product to veterinarians in Canada,” added Graeme McRae, President & CEO of Bioniche Life Sciences Inc., “particularly one that has been developed by Bioniche and manufactured to our consistently high standards by our staff in Ireland.”
About Bioniche Animal Health
The Animal Health Division of Bioniche Life Sciences Inc. has marketing subsidiaries in Australia, Canada, Europe, and the United States. It is responsible for research, development, manufacturing, and marketing of veterinary biologics, pharmaceuticals, and nutritionals. This Division has a global portfolio of 60 products, which fall into the categories of: reproduction and embryo transfer; immunostimulant; and vaccines.
About Bioniche Life Sciences
Bioniche Life Sciences Inc. is a leading, fully-integrated Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The Company employs more than 300 individuals and has three principal operating divisions: Animal Health, Food Safety, and Human Health, which includes Bioniche Therapeutics and Bioniche Pharma Group. For more information, please visit http://www.bioniche.com/.
Except for historical information, this news release may contain forward- looking statements that reflect the Company’s current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting.
Bioniche Life Sciences Inc.
CONTACT: Jennifer Shea, Corporate Communications Manager, Bioniche LifeSciences Inc., +1-613-966-8058 ext. 1250, or Cell, +1-613-331-6432,Jennifer.Shea@Bioniche.com; Rachel Levine, Investor Relations, The AnneMcBride Company, +1-212-983-1702 ext. 207, Rlevine@annemcbride.com, forBioniche Life Sciences Inc.
Web site: http://www.bioniche.com/